Ola M Saad

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3644444/publications.pdf

Version: 2024-02-01

32 papers	2,621 citations	489802 18 h-index	488211 31 g-index
32 all docs	32 docs citations	32 times ranked	2723 citing authors

#	Article	IF	Citations
1	Multiplexed Quantitative Analysis of Antibodyâ€“Drug Conjugates with Labile CBI-Dimer Payloads In Vivo Using Immunoaffinity LC-MS/MS. Analytical Chemistry, 2022, 94, 1158-1168.	3.2	2
2	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. Molecular Cancer Research, 2020, 18, 644-656.	1.5	17
3	Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates. Analytical Chemistry, 2020, 92, 12168-12175.	3.2	9
4	Characterization of Tissue Distribution, Catabolism, and Elimination of an Antiâ€“Staphylococcus aureusTHIOMAB Antibody-Antibiotic Conjugate in Rats. Drug Metabolism and Disposition, 2020, 48, 1161-1168.	1.7	9
5	Immunogenicity of antibodyâ€“drug conjugates: observations across 8 molecules in 11 clinical trials. Bioanalysis, 2019, 11, 1555-1568.	0.6	25
6	Preclinical and translational pharmacokinetics of a novel THIOMABâ„¢ antibody-antibiotic conjugate against Staphylococcus aureus. MAbs, 2019, 11, 1162-1174.	2.6	22
7	A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	59
8	Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte. Analytical and Bioanalytical Chemistry, 2019, 411, 2587-2596.	1.9	6
9	Antibodyâ€“Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjugate Chemistry, 2019, 30, 1356-1370.	1.8	15
10	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 â€“ PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.6	26
11	Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. MAbs, 2018, 10, 1312-1321.	2.6	13
12	Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMABâ„¢ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model. MAbs, 2018, 10, 1-13.	2.6	8
13	Platform model describing pharmacokinetic properties of vc-MMAE antibodyâ€“drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 537-548.	0.8	9
14	Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. AAPS Journal, 2017, 19, 130-140.	2.2	14
15	2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part) Tj ETQq1 1 0.784314 rgBT /O	0.6	32
16	Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMABâ„¢ antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs, 2016, 8, 1612-1619.	2.6	59
17	Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1). Clinical Cancer Research, 2015, 21, 123-133.	3.2	142
18	Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Pharmaceutical Research, 2015, 32, 1907-1919.	1.7	15

#	Article	IF	Citations
19	Bioanalytical approaches for characterizing catabolism of antibodyâ€“drug conjugates. Bioanalysis, 2015, 7, 1583-1604.	0.6	28
20	Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. Drug Metabolism Letters, 2015, 9, 119-131.	0.5	17
21	Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicology and Applied Pharmacology, 2013, 273, 298-313.	1.3	162
22	Effects of Trastuzumab Emtansine (Tâ€ĐM1) on QT Interval and Safety of Pertuzumab Plus Tâ€ĐM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Clinical Pharmacology in Drug Development, 2013, 2, 11-24.	0.8	33
23	PK assays for antibodyâ€“drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis, 2013, 5, 1025-1040.	0.6	58
24	Bioanalytical assay strategies for the development of antibodyâ€“drug conjugate biotherapeutics. Bioanalysis, 2013, 5, 201-226.	0.6	205
25	Mass Spectrometry of Antibodyâ€“Drug Conjugates in Plasma and Tissue in Drug Development. , 2013, , 279-304.		7
26	Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism. Current Drug Metabolism, 2012, 13, 901-910.	0.7	116
27	Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature Biotechnology, 2012, 30, 184-189.	9.4	849
28	Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibodyâ€“drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 1229-1240.	1.1	230
29	Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibodyâ€“Drug Conjugates in Rats. Bioconjugate Chemistry, 2011, 22, 1994-2004.	1.8	177
30	Characterization of intact antibodyâ€“drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatographyâ€“mass spectrometry. Analytical Biochemistry, 2011, 412, 56-66.	1.1	174
31	Abstract A136: Nonclinical disposition, metabolism, and in vitro drug-drug interaction assessment of DM1, a component of trastuzumab emtansine (T-DM1).. Molecular Cancer Therapeutics, 2011, 10, A136-A136.	1.9	10
32	Anti-CD22-MCC-DM1 and MC-MMAF Conjugates: Impact of Assay Format on Pharmacokinetic Parameters Determination. Bioconjugate Chemistry, 2008, 19, 1673-1683.	1.8	73